Xarostat-ASP 20 Capsule is a combination pharmaceutical formulation containing Rosuvastatin 20 mg and Aspirin 75 mg, indicated for the management of cardiovascular risk in patients with hyperlipidemia and a history of or risk for atherosclerotic cardiovascular disease (ASCVD). Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C), total cholesterol, and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C). Aspirin, an antiplatelet agent, irreversibly inhibits cyclooxygenase-1 (COX-1), reducing thromboxane A2 production and thereby decreasing platelet aggregation, which helps prevent thrombotic events such as myocardial infarction and stroke. The combined therapy of Rosuvastatin and low-dose Aspirin provides synergistic benefits by addressing both lipid abnormalities and platelet-mediated thrombosis, essential in secondary prevention of cardiovascular events. Xarostat-ASP 20 Capsule is typically prescribed once daily, preferably with food, and requires regular monitoring of lipid profiles, liver function tests, and assessment for potential adverse effects such as myopathy, hepatotoxicity, and gastrointestinal irritation. Caution is advised in patients with bleeding disorders, active peptic ulcer disease, or hypersensitivity to either component. This combination therapy should be used under strict medical supervision to optimize cardiovascular outcomes and minimize risks.